Skip to main content
. Author manuscript; available in PMC: 2010 May 15.
Published in final edited form as: J Neurosci Res. 2009 May 15;87(7):1645–1658. doi: 10.1002/jnr.21978

Fig. 6.

Fig. 6

Direct striatal infusions of ±8-OH-DPAT dose- and receptor-dependently reduce ALO AIMs expression. In counterbalanced within-subject designs, one group of L-DOPA-primed rats (n = 10) received intrastriatal microinfusions of vehicle (VEH) or ±8-OH-DPAT (D-5.0 or 10.0 μg/side) 5 min after treatments of L-DOPA + benserazide (12 + 15 mg/kg, i.p.), after which (A) ALO AIMs and (B) rotations were observed every 20 min for 2 hr. In a separate group of L-DOPA-primed rats (n = 8) 5 min after intrastriatal microinfusions of vehicle (VEH), 10.0 μg/side of ±8-OH-DPAT (D-10.0), 5.0 μg/side of WAY100635 (W-5.0), or combined 8-OH-DPAT + WAY100635 (10.0 + 5.0 μg/side; D+W), rats received treatments of L-DOPA + benserazide (12 + 15 mg/kg, i.p.), after which (C) ALO AIMs and (D) rotations were assessed every 20 min for 2 hr. Symbols represent averaged ALO AIMs and net rotations ± SEM at each time point of testing. ALO AIMs were analyzed by nonparametric Friedman ANOVAs. Two-way parametric ANOVAs were used for analysis of rotations. Post hoc comparisons denote significant differences between treatments as indicated. *P < 0.05 vs. VEH, +P < 0.05 vs. D-5.0, #P < 0.05 vs. D+W.